{"Title": "Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study", "Year": 2020, "Source": "Neurol Neuroimmunol Neuroinflamm", "Volume": "7", "Issue": 5, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 1, "DOI": "10.1212/NXI.0000000000000837", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088885156&origin=inward", "Abstract": "Copyright \u00a9 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.OBJECTIVE: To describe the clinical phenotypes, treatment response, and outcome of children with antibodies against aquaporin-4 (AQP4-Ab) neuromyelitis optica spectrum disorder (NMOSD). METHODS: Retrospective, multicenter, and multinational study of patients with AQP4-Ab NMOSD aged <18 years at disease onset from a center in Brazil and 13 European centers. Data on demographics, clinical findings, and laboratory results were analyzed; calculation of annualized relapse rates (ARRs) pre- and on-treatment with disease-modifying therapies (DMTs) and of ORs for predictors of poor outcome was performed. RESULTS: A total of 67 children were identified. At last follow-up (median 4 years, interquartile range 2-10 years), 37/67(57.8%) were found to have permanent disability. A more severe disease course was seen in the non-White ethnicity with both a shorter time to first relapse (p = 0.049) and a worse Expanded Disability Status Scale score at last follow-up (p = 0.008). The median ARR on treatment was 0.18 on azathioprine (n = 39, range 0-4), 0 on mycophenolate mofetil (n = 18, range 0-3), and 0 on rituximab (n = 29, range 0-2). No patient treated with rituximab as first-line therapy relapsed. Optic neuritis at onset was associated with a poor visual outcome below 20/200 (OR 8.669, 95% CI 1.764-42.616, p = 0.008), and a younger age at onset was associated with cognitive impairment (OR 0.786, 95% CI 0.644-0.959, p = 0.018). CONCLUSIONS: AQP4-Ab NMOSD in children is an aggressive disease with permanent disabilities observed in over half the cohort. All DMTs were associated with a reduction of ARR. First-line rituximab prevented further clinical relapses. International consensus on treatment protocols for children is required to reduce heterogeneity of treatment regimens used worldwide. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for children with AQP4-Ab NMOSD, all DMTs, particularly first-line rituximab, reduced the ARR and prevented further clinical relapses.", "AuthorKeywords": null, "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85088885156", "SubjectAreas": [["Neurology", "NEUR", "2808"], ["Neurology (clinical)", "MEDI", "2728"]], "AuthorData": {"57218352318": {"Name": "Paolilo R.B.", "AuthorID": "57218352318", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "14631844100": {"Name": "Hacohen Y.", "AuthorID": "14631844100", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57216490911": {"Name": "Yazbeck E.", "AuthorID": "57216490911", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "55179338000": {"Name": "Armangue T.", "AuthorID": "55179338000", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57210901619": {"Name": "Bruijstens A.", "AuthorID": "57210901619", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "56318260600": {"Name": "Lechner C.", "AuthorID": "56318260600", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "6504412418": {"Name": "Apostolos-Pereira S.L.", "AuthorID": "6504412418", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57218351545": {"Name": "Martynenko Y.", "AuthorID": "57218351545", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "55605286300": {"Name": "Breu M.", "AuthorID": "55605286300", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57219333409": {"Name": "de Medeiros Rimkus C.", "AuthorID": "57219333409", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "6603875837": {"Name": "Wassmer E.", "AuthorID": "6603875837", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57192396644": {"Name": "Baumann M.", "AuthorID": "57192396644", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57220359390": {"Name": "Papetti L.", "AuthorID": "57220359390", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57201987331": {"Name": "Capobianco M.", "AuthorID": "57201987331", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "6602773799": {"Name": "Kornek B.", "AuthorID": "6602773799", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "55938543700": {"Name": "Rost\u00e1sy K.", "AuthorID": "55938543700", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57218352123": {"Name": "da Paz J.A.", "AuthorID": "57218352123", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "7003671038": {"Name": "Ciccarelli O.", "AuthorID": "7003671038", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57220743920": {"Name": "Lim M.", "AuthorID": "57220743920", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "57220450076": {"Name": "Saiz A.", "AuthorID": "57220450076", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "16835025800": {"Name": "Neuteboom R.", "AuthorID": "16835025800", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "24462285700": {"Name": "Marignier R.", "AuthorID": "24462285700", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "35388344100": {"Name": "Hemingway C.", "AuthorID": "35388344100", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "37031923100": {"Name": "Sato D.K.", "AuthorID": "37031923100", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}, "6504269075": {"Name": "Deiva K.", "AuthorID": "6504269075", "AffiliationID": "60019953, 60013430, 60022148, 60018207", "AffiliationName": null}}}